A report released today by Zacks Investment Research about Edap Tms SA (ADR) (NASDAQ:EDAP) raises the target price to $3.25
- Updated: October 11, 2016
Boasting a price of $2.85, Edap Tms SA (ADR) (NASDAQ:EDAP) traded 4.78% higher on the day. With the last stock price close down -12.45% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Edap Tms SA (ADR) has recorded a 50-day average of $2.91 and a two hundred day average of $3.26. Volume of trade was up over the average, with 112,415 shares of EDAP changing hands over the typical 62,078
In a statement issued on 10/11/2016 Zacks Investment Research bumped up the stock price target of Edap Tms SA (ADR) (NASDAQ:EDAP) to $3.25 indicating a possible upside of 0.14%.
With a total market value of $0, Edap Tms SA (ADR) has price-earnings ratio of 17.38 with a one year low of $2.43 and a one year high of $6.57 .
Brief Synopsis About Edap Tms SA (ADR) (NASDAQ:EDAP)
EDAP TMS S.A. (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other types of urology devices in certain countries. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the invasive treatment of urological and other clinical indications. The UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the invasive diagnosis or treatment of urological disorders, urinary stones, and other clinical indications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.